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and pulmonary alveolar proteinosis
Bruce C Trapnell1 and Maurizio Luisetti2*Abstract
In 1963, five cases of alpha1-antitrypsin deficiency were reported in the scientific literature, as well as an attempt
to treat pulmonary alveolar proteinosis by a massive washing of the lung (whole lung lavage). Now, fifty years later,
it seems the ideal moment not only to commemorate these publications, but also to point out the influence both
papers had in the following decades and how knowledge on these two fascinating rare respiratory disorders
progressed over the years. This paper is therefore not aimed at being a comprehensive review for both disorders,
but rather at comparing the evolution of alpha1-antitrypsin, a rare disorder, with that of pulmonary alveolar
proteinosis, an ultra-rare disease. We wanted to emphasize how all stakeholders might contribute to the
dissemination of the awareness of rare diseases, that need to be chaperoned from the ghetto of neglected
disorders to the dignity of recognizable and treatable disorders.
Keywords: Alpha1-proteinase inhibitor, Pulmonary emphysema, Whole lung lavageIntroduction
In 1963 the world was in a state of fermentation, which
eventually exploded in the second half of the sixties on
both sides of the Atlantic Ocean and in different areas:
affecting social life, the arts and protest movements. See
Additional file 1 for a historic landscape. The world of
Science in the meantime was thrilled by the first human
organ transplants for liver, lung, and kidney. Two much
less thrilling articles, but which had a great impact in
the following years, were published in 1963. Carl- Bertil
Laurell (Figure 1) and Sten Eriksson at the Malmö
University in Sweden reported on five cases of serum
alpha1-antitrypsin (AAT) absence in the electrophoresis;
interestingly three out the five carriers suffered from
pulmonary emphysema [1,2]. Almost simultaneously,
three physicians from the Johns Hopkins University,
led by Jose Ramirez-Rivera, (Figure 2) experimented
with the segmental flooding technique by means of an
endobronchial catheter [3] to remove the accumulated
material within the airspaces in a young male affected
by pulmonary alveolar proteinosis, a mysterious disease
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distribution, and reproduction in any mediumcolleagues [4]. At the moment of publication, neither
paper was enthusiastically acclaimed, but now fifty years
after their original release it seems the ideal moment not
only celebrate their publication, but most of all point out
the influence both papers had in the following decades
and how knowledge on these two fascinating rare re-
spiratory disorders progressed over the years.From sixties to eighties
The ten years following this discovery were marked with
events of a lifetime for alpha1-antitrypsin deficiency
(AATD) in Sweden. In his captivating review [5], Robin
Carrell told how the original description of Laurell &
Eriksson promoted an extraordinary, lively and productive
environment in Sweden, and in Malmö in particular.
Kjell Ohlsson, Jan Olof Jeppson, Magne Fagerhöl and
Diane Cox, the latter arriving in Malmö from Norway
and Canada, respectively, focused their work on the
explanation of the complex electrophoretic heterogeneity
of AAT, eventually contributing to the development of Pi
nomenclature for AAT variants [6-8]. In the meantime,
Christeer Larson provided evidence for the interaction
of smoking with AATD [9], thus contributing to the
current oxidation stress/proteinase imbalance hypothesis
of the pathogenesis of emphysema, and Tomas Sveger
performed the Swedish newborn national screening forCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Carl-Bertil Laurell (Courtesy of eALTA Grifols).
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disorder [10]. To complete the Scandinavian perspective,
the same investigators detected the inclusion of AAT
within hepatocytes of AATD subjects with liver disease
[11], a finding that was however anticipated a few years
before by Dr Sharp and colleagues in the US [12].
The next decade was equally productive for AATD
research. On the one hand, the reactive site of AAT was
identified, as well as its vulnerability to oxidant stress
[13,14]. On the other hand, the crystallographic structure
of AAT was elucidated and the first hypothesis was
proposed that AATD was due to a structural perturb-
ation hampering the extracellular secretion of the mature
protein [15,16]. From the molecular perspective, the
mid-eighties were marked by successful cloning andFigure 2 José Ramirez Rivera with a young pulmonary staff
member at University of Puerto Rico, 2012.sequencing of the human AAT gene (currently named
SERPINA1), and the identification of the point mutation
underlying the AATD Z variant [17,18]. In the meantime,
reports of longitudinal studies progressively improved our
knowledge on the natural history and clinical phenotypes
of individuals with AATD-associated clinical conditions
[19]. The decade ended with the hallmark study on the
feasibility of purified protein replacement therapy in
AATD deficiency subjects [20].
The two decades following the original whole lung
lavage (WLL) description were not so eventful. The major
advance achieved during this period, as reported by
Seymour and Presneill in their review [21], was the pro-
gressive improvement of the original washing technique
described by Ramirez-Rivera, which matured into the
WLL as we know it today [22]: the adoption of general
anesthesia, the progressive increase of fluid volume, the
usefulness of chest percussion, ending with the successful
lavage of both lungs in the same session. Most papers
published in this period were anecdotal studies of the
disorder, they did however contribute to the expansion
of our knowledge. Interestingly, some of these reports,
although not directly addressing the pathogenesis of PAP,
pointed to some aspects of the disease heterogeneity and
development. The induction of proteinosis in the animal
model of silica exposure [23], and the report on PAP
occurrence in a subjects with heavy exposure to aluminum
dust [24], as well as the report on rare cases of PAP in
patients with hematological malignant disease [25] foresaw
some of the forms of secondary PAP. The report on
familial clustering of cases of PAP [26] described the
occurrence of hereditary proteinosis, whereas the presence
of newborn PAP as a cause of neonatal respiratory distress
syndrome [27] first reported the so called PAP-like forms
due to surfactant protein genetic abnormalities. Patho-
genesis of the most common form of PAP, referred to
as idiopathic, was unknown at that time, and bound to
remain so for several decades, but David W Golde in
1976 focused his attention on the defective activity of
lipid-laden macrophages [28], a cell that eventually was
recognized to play a pivotal role in the development of
PAP. In their paper published in 1984, William Claypool
and colleagues [29] reviewed the current status of
knowledge on pathogenesis and management of PAP:
they carefully described their experience with 34 PAP
patients, the single lung, whole lavage technique, and
reviewed possible steps in PAP pathogenesis, concluding
that the pathophysiology of surfactant disorders such as
PAP would challenge scientists and physicians in the
future: this held true for at least 10 more years.
The next twenty years : form nineties to 2010
Progress in the study of AATD from 1990 to 2010
proceeded in different directions. The AATD disease
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frequent AAT variant associated with severe deficiency,
Glu342Lys, also referred to as PI*Z, was shown to form
polymers and accumulate within hepatocytes [30], causing
the deficiency in the bloodstream. This led to the
hypothesis of a divergent mechanism for lung and liver
disease in AATD: a deficiency mechanism (“loss-of-
function”) in lung disease, and an add-on, related to the
misfolding of the protein (“gain-of-function”), a con-
formational mechanism in liver disease [31,32]. This
Manichean view was however complicated by evidence
that PI*Z polymers may also be detected and likely
produced within the lung [33], thus suggesting that the
add-on mechanism could also contribute to lung disease.
A large series of AATD patients were studied in the
United States and United Kingdom during this period,
and greatly contributed to our knowledge on the clinical
presentation and natural history of lung disease associated
with AATD, in terms of mortality, FEV1 decline, and exac-
erbations [34-36], as well as the associated liver disease
[37]. The epidemiology of AATD received great attention
after the publication of the worldwide analysis by Fredrick
de Serres: in his estimation, albeit in part refined in
numerous subsequent publications, ca. 30,000,000 individ-
uals are at risk for adverse health effects due to different
AATD genotypes [38]. Replacement therapy with i.v.
infusion of purified human plasma protein was licensed in
the last decade of the Twentieth Century, and progres-
sively became available. As a result, thousands of patients
with lung disease associated with AATD have been safely
treated [39,40]: a meta-analysis of observational studies
confirmed efficacy with the decreasing decline of lung
function in treated patients with an initial FEV1 between
30 and 65% predicted [41]. A number of alternative
treatments for AATD have been proposed, ranging
from inhalation therapy to recombinant and transgenic
AAT, from gene therapy to regenerative medicine
[42-45]: none of these options has so far gone beyond
the experimental stage. AATD played a critical role in
the last two decades in building one of the most long-lived
and respected hypotheses for the development of common
pulmonary emphysema: the theory of an imbalance
between proteinases and proteinase inhibitors, took
shape, which evolved over the years, with the biochemical
evidence of emphysema in subjects lacking AAT [46].
At the beginning of the last 1990’s, compared with
AATD, PAP lagged behind in terms of knowledge on
pathogenesis. But it quickly made up for lost time: in 1994
two papers demonstrated simultaneously and serendipit-
ously that mice lacking GM-CSF (granulocyte-macro-
phage colony-stimulating factor) developed a lung disease
similar to human PAP [47,48]. These data showed that
GM-CSF is critical for surfactant homeostasis in the lung,
leading to subsequent studies and evidence that PAP wasrelated to impaired surfactant catabolism by alveolar
macrophages [49]. However the etiology of surfactant
impairment in PAP remained unexplained until 1999,
when Koh Nakata and coworkers demonstrated the
presence of polyclonal, neutralizing anti-GM-CSF auto-
antibodies (GMAbs) in patients with “idiopathic” PAP
[50]. Shortly thereafter, the pathogenesis of PAP in GM-
CSF-deficient mice was elucidated in a study demonstrating
that pulmonary GM-CSF is required for the terminal
differentiation of alveolar macrophages [51]. Subsequently,
passive transfer studies in non-human primates injected
with purified human PAP patient-derived GMAbs pro-
vided proof of their role in pathogenesis of PAP in
humans (and of the critical role of GM-CSF in terminal
differentiation of alveolar macrophages in primates) [52].
These and other studies helped to define the previously
designated “idiopathic” PAP as an autoimmune disorder
and led to a new classification of surfactant disorders,
including secondary PAP and rare forms of hereditary
PAP [53]. The progressive evolution and improvements
in the WLL technique over the years dramatically changed
the natural course of the disease, which was originally
charged with a mortality of approximately 30%, it pro-
gressively became a disease with a substantially favorable
prognosis [21]. In the 70% of PAP patients a single
WLL is enough to provide a prolonged period free of
disease and/or symptoms [54]. Although WLL is a relatively
safe procedure in experienced hands, it is however an
invasive procedure, not exempt from severe complications.
Therefore based on novel pathogenesis insights, novel
therapeutic options have sprung [55]. To restore appro-
priate GM-CSF signaling, impaired by the presence of
GMAbs, supplementation with exogenous recombinant
GM-CSF has been proposed, first by subcutaneous in-
jection, and then by inhalation [56,57]; results were
substantially better with the latter delivery method.
Considering the mechanisms underlying the autoimmune
form of PAP, a biological approach seemed reasonable. An
open-label trial investigating Rituximab treatment which
depletes the CD20 B-cell population provided intriguing,
preliminary results [58].
Achievements in the first fifty years and expectations for
the future
As with any anniversary, retrospection and introspection
are in order. We should address the basic question: what
contributions have been made during these 50 years to
our understanding and management of these two rare
respiratory diseases (Figure 3). The answer is largely
positive, although with understandable differences:
 AATD and PAP are both rare respiratory disorders,
but with remarkable differences in prevalence, now
recognized at: 33/100,000 for AATD and 0.7/1100.000
1963 20131970 1980 1990 2000 2010
AATD
PAP
Figure 3 Milestones of the fifty years progress in the knowledge of AATD and PAP.
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diseases (i.e. rare disease with a prevalence < 1/
100,000 individuals).
 In spite of this difference, although a formal registry
for PAP is not available, published data for more
than 1,000 PAP patients are available [61]. On the
other hand, two large registries for AATD are active,
one in the US (Alpha-1 Research Registry), and the
second is an international registry (Alpha One
International Registry, AIR) [62], with about a total
of 9,500 AATD patients enrolled. Such a large series
of patients will contribute to a better understanding
of the natural history of both diseases.
 A marked difference is however evident in
molecular epidemiology data, since we have a
comprehensive view for AATD [63], whereas PAP
data are scattered and incomplete.
 Large diagnostic programs for AATD have been
established over the last two decades in Western
countries [64], with consolidated diagnostic
flow-charts for genetic testing, and new programs
are currently going to be implemented in Eastern
Europe, whereas for PAP we are at the early stage of
establishment of reference centers in the US and
Europe. However we are at a satisfactory stage,
compared with the very recent past.
 Powerful patient-advocacy groups for AATD are
active both in the US [65] and Europe, whereas a
PAP patient organization is present only in the US
[66] and its activity is very limited.
 Thousands of AATD patients are currently on
replacement therapy in both the Americas and in
Europe; in contrast, WLL is not a standardized
procedure, and is available only in selected centers.
A worldwide census of centers with experienceperforming WLL [67] hopefully will represent the
first step toward standardizing the procedure.
 Last, but not least: the search for surrogate markers
to prove efficacy of replacement therapy in AATD,
has greatly contributed to the development of
computed tomography-based lung densitometry
[68-70], a technique likely to be implemented in
common emphysema [71] for testing new potentially
active drugs.
Major review articles are available for both disorders:
at least three for AATD, covering different aspects of the
disease [72-75], and one for PAP (75).
On a final note, we would like to express our expecta-
tions for the coming years. The AATD community is
anxiously waiting for unbiased proof of efficacy for
replacement therapy and, in turn, an alignment in acces-
sibility to therapy among European countries. Research
will hopefully address alternatives to plasma purification
of AAT, in order to improve efficacy, reduce costs, and
broaden availability: inhalation delivery, recombinant
AAT, as well as regenerative medicine, and drugs able to
correct misfolded AAT are all under active investigation,
as stated above. On the other hand, it is desirable that
detection programs reduce the huge gap between diag-
nosed and estimated individuals with severe AATD,
making epidemiology data more robust. The path for
PAP is understandably longer, but hopefully not winding.
Registries, standards of care, networks/centers of excel-
lence, precise epidemiology (does ultra-rare status stem
from ignorance?), patient advocacy for PAP are still in the
embryonic stage. Lessons from AATD should be extended
to PAP, with the hope that it will share the same interest
as AATD: biological treatments will hopefully help achieve
this goal. This would definitely bring PAP out of the
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AATD, converging into the dignity of rare diseases with
equal awareness. It is hoped that such a process does not
require fifty more years.
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